Previous Close | 32.64 |
Open | 32.39 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's Range | 32.15 - 32.45 |
52 Week Range | 31.77 - 40.48 |
Volume | |
Avg. Volume | 1,750,196 |
Market Cap | 208.632B |
Beta (5Y Monthly) | 0.15 |
PE Ratio (TTM) | 15.93 |
EPS (TTM) | 2.02 |
Earnings Date | N/A |
Forward Dividend & Yield | 1.39 (4.33%) |
Ex-Dividend Date | Mar 14, 2024 |
1y Target Est | 37.79 |
Subscribe to Yahoo Finance Plus to view Fair Value for RHHBY
The biotech, formed as a successor to a company Roche acquired in 2018, has two drugs in clinical testing for neurological and immune diseases.
Advances in Clinical Trials and Strategic Collaboration Mark Year's Achievements
Roche (RHHBY) is likely to enter the growing diabetes market with its AI-enabled predictive glucose monitoring system that may revolutionize diabetes management.